SS-31 (Elamipretide): Mitochondrial Science, FDA Approval, Benefits, and Research

Meta title: SS-31 Elamipretide: Uses, Mitochondrial Research, and Safety
Meta description: Learn what SS-31, also called elamipretide, is; how it targets mitochondrial cardiolipin; its FDA-approved use for Barth syndrome; and what researchers are still investigating.

SS-31, better known today as elamipretide, is designed to act within mitochondria. These structures generate most of the chemical energy used by cells, so mitochondrial dysfunction is connected to numerous inherited and acquired diseases.

For years, elamipretide was described entirely as an investigational mitochondrial peptide. That changed in September 2025, when the U.S. Food and Drug Administration granted accelerated approval to Forzinity, an elamipretide injection, for a narrow and specific medical use. It became the first approved treatment for Barth syndrome in patients weighing at least 30 kilograms.

That approval was an important milestone, but it did not establish elamipretide as a general treatment for fatigue, exercise performance, aging, heart disease, kidney disease, or every condition involving mitochondrial stress. The science remains more precise—and more limited—than many online descriptions suggest.

This guide examines what SS-31 is, how it interacts with mitochondria, what accelerated approval means, what clinical research has found, and why approved medicine should be distinguished from unapproved or research-use-only products.

What Is SS-31?

SS-31 is one of several names used during the development of elamipretide. It has also appeared in scientific literature as MTP-131 and Bendavia. The FDA-approved product is sold under the brand name Forzinity.

Elamipretide is a small peptide made from four amino-acid residues, making it a tetrapeptide. The approved drug’s sequence is described in FDA labeling as D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2. Unlike many larger biological molecules, elamipretide is designed to enter cells and concentrate at the inner mitochondrial membrane.

The FDA classifies Forzinity as a mitochondrial cardiolipin binder. Cardiolipin is a specialized phospholipid in the inner mitochondrial membrane that contributes to energy-production proteins, signaling, and membrane stability.

This mitochondrial target explains why elamipretide has been investigated across several diseases. However, sharing a biological feature does not mean that different diseases will respond to the same treatment. Mitochondrial dysfunction can arise from many distinct genetic variants, cellular injuries, and disease mechanisms.

Why Mitochondria Matter

Mitochondria are often called the powerhouses of the cell. That description is simplified, but it captures one essential job: converting energy from nutrients into adenosine triphosphate, or ATP. Cells use ATP to power muscle contraction, nerve activity, transport molecules, maintain ion gradients, and perform numerous other functions.

Energy production occurs largely through oxidative phosphorylation. Protein complexes in the inner membrane transfer electrons and create the gradient needed to produce ATP, making membrane organization central to efficient energy metabolism.

Mitochondria also participate in calcium signaling, stress responses, programmed cell death, and control of reactive oxygen species. In excess, these reactive molecules can damage lipids, proteins, and genetic material.

When mitochondrial structure or function is severely disrupted, tissues with high energy requirements can be especially affected. The heart, skeletal muscles, nervous system, eyes, kidneys, and other organs may be vulnerable. This helps explain why inherited mitochondrial disorders can produce complicated symptoms across multiple body systems.

How Elamipretide Is Thought to Work

Elamipretide localizes to the inner mitochondrial membrane and interacts with cardiolipin. According to the FDA-approved prescribing information, this activity improves mitochondrial morphology and function. Researchers have proposed that cardiolipin binding may help stabilize the membrane environment supporting the electron transport chain.

Preclinical research has explored whether elamipretide can improve electron transport, support ATP production, limit damaging oxidative stress, and preserve mitochondrial structure under disease conditions. Those findings created interest in using the peptide for disorders involving impaired cellular energy production.

A plausible mechanism and positive laboratory data do not prove that a drug improves every human disease. Many compounds affect biological markers in cells or animals but fail to show meaningful clinical benefits in controlled trials.

Elamipretide’s FDA approval is connected specifically to evidence in Barth syndrome—not to a general claim that it “repairs mitochondria” in healthy people. Consumers should be skeptical of marketing that turns a complicated mechanism into promises of universal energy, anti-aging effects, faster recovery, or enhanced athletic performance.

FDA Approval for Barth Syndrome

On September 19, 2025, the FDA granted accelerated approval to Forzinity to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kilograms. The agency described it as the first treatment approved for this rare mitochondrial disease.

Barth syndrome is a rare, serious, and potentially life-threatening genetic disorder that primarily affects males. It is caused by pathogenic variants involving the TAZ gene, which disrupt cardiolipin remodeling and mitochondrial function. Clinical features may include cardiomyopathy, muscle weakness, poor growth, low stamina, fatigue, exercise intolerance, and neutropenia, which is an abnormally low level of certain white blood cells.

Symptoms vary. Some infants develop severe heart failure, while adolescents and adults may face significant limitations in endurance and daily functioning. Because the disorder directly involves cardiolipin biology, elamipretide provided a rational target.

Forzinity is administered as a subcutaneous injection. It is a prescription medicine with official labeling, defined manufacturing standards, patient instructions, and professional monitoring requirements. Its approved use should not be confused with unapproved SS-31 products offered by online research suppliers.

What Accelerated Approval Means

Accelerated approval allows the FDA to approve a drug for a serious condition based on an intermediate or surrogate endpoint that is reasonably likely to predict clinical benefit. This pathway can provide earlier access when patients have an unmet medical need, but additional evidence is required.

Forzinity’s approval was based on improvement in knee-extensor muscle strength. The FDA considers that improvement reasonably likely to predict benefits such as standing more easily or walking farther. However, this intermediate measurement does not itself establish every possible real-world benefit.

As a condition of accelerated approval, the manufacturer must conduct a randomized, double-blind, placebo-controlled post-approval study. That confirmatory trial is intended to determine whether the improvement in muscle strength translates into a verified benefit for patients.

Continued approval can depend on confirmation and description of that clinical benefit. This distinction is essential when discussing the strength of the evidence. Accelerated approval is genuine FDA approval, but it comes with an obligation to verify the expected outcome through further study. 

What Clinical Studies Have Shown

Barth syndrome is extremely rare, making large conventional trials difficult. The clinical development program included a small randomized crossover study followed by an open-label extension. In a crossover design, participants receive both the investigational treatment and placebo during different periods.

The initial controlled phase did not produce a positive result across every outcome. Longer-term observations supported continued study, and the FDA ultimately based accelerated approval on improvement in knee-extensor strength.

Small trials require careful interpretation. Results can be influenced by variation, participant differences, performance-test learning effects, and missing data. Open-label extensions provide useful information, but participants and researchers know which treatment is administered.

Research outside Barth syndrome has also produced mixed findings. Elamipretide has been studied in primary mitochondrial myopathy, an umbrella category involving disorders that impair mitochondrial energy production. A large Phase 3 study did not meet its primary endpoints across the overall population. Later post hoc analyses suggested that certain genetic subgroups might respond differently, generating hypotheses for more targeted trials. 

The lesson is not that elamipretide never works outside Barth syndrome, nor that it is broadly effective. The correct conclusion is that effects may depend on the disease and genetic mechanism, and additional controlled research is required.

Other Areas of Elamipretide Research

Because mitochondrial dysfunction occurs in many conditions, investigators have evaluated or proposed elamipretide in several areas, including primary mitochondrial myopathy, heart failure, kidney disease, inherited neurodegenerative disorders, ophthalmic disease, and age-related functional decline.

The rationale varies by condition. Cardiac studies have explored heart-muscle energetics; kidney studies have examined cellular stress; and neuromuscular research has focused on fatigue, weakness, and impaired energy production.

These research programs do not establish approved uses. A disease may involve mitochondrial dysfunction without mitochondrial dysfunction being the only cause—or even the best therapeutic target. Trials may show changes in laboratory measurements while failing to improve symptoms, function, hospitalization, or survival.

Consumers should distinguish among preclinical research, early safety studies, randomized trials, post hoc subgroup analyses, and FDA approval. Each provides a different level of evidence. Statements such as “studied for” or “supports mitochondrial health” can conceal that a proposed use remains unproven.

Side Effects and Safety

The FDA-approved label reports that the most common adverse effects of Forzinity are injection-site reactions. These can include redness, pain, itching, bruising, firmness, swelling, or hives at the injection area.

Hypersensitivity reactions have also occurred, including serious allergic reactions requiring emergency treatment. Reported manifestations have included rash, dermatitis, and respiratory symptoms such as coughing. Reactions may develop soon after treatment begins or after a longer period. A person experiencing breathing difficulty, widespread rash, facial swelling, or another sign of a severe allergic reaction should seek emergency medical care.

Kidney function matters because elamipretide and its metabolites are excreted in urine. The approved label includes specific considerations for severe renal impairment and notes areas where evidence is insufficient. Pregnancy, breastfeeding, allergies, and all medications or supplements should be discussed with the prescribing clinician.

Forzinity contains benzyl alcohol as a preservative and is not approved for neonates. Patients and caregivers should follow the official medication guide, storage requirements, injection instructions, and monitoring plan. 

Safety information from an approved product cannot automatically be applied to unapproved preparations. Differences in identity, concentration, sterility, contaminants, storage, or labeling can create additional risks.

Research-Use-Only SS-31 Is Not Forzinity

The existence of an FDA-approved elamipretide medicine does not convert every vial marked “SS-31” into an approved drug. Forzinity is manufactured and distributed under a specific regulatory approval for a defined patient population. Research-use-only SS-31 is intended for laboratory investigation, not human administration.

Claims such as “99 percent purity,” “third-party tested,” or “made in the USA” do not demonstrate sterility, clinical effectiveness, appropriate dosing, or equivalence to the approved product. A certificate of analysis may describe certain laboratory tests, but it is not an FDA approval and does not establish suitability for injection.

Warning signs include a seller providing human dosing instructions for a research product, promoting SS-31 for bodybuilding or anti-aging, offering treatment without a prescription, or implying that a research vial is a lower-cost version of Forzinity.

Patients with diagnosed or suspected Barth syndrome should receive care from clinicians experienced in rare mitochondrial disease and discuss appropriate treatment and monitoring.

The Future of Mitochondria-Targeted Medicine

Elamipretide represents an important step in mitochondria-targeted drug development. It also illustrates how complex that field can be. A drug may have an elegant mechanism, strong laboratory rationale, mixed findings across broad trials, and meaningful potential within a narrowly defined genetic disease.

Future research may identify additional patient groups whose specific biology makes them more likely to respond. Better genetic classification, biomarkers, trial endpoints, and functional assessments could help researchers avoid treating diverse mitochondrial disorders as if they were one condition.

The required confirmatory study in Barth syndrome will be especially important. It should clarify whether the muscle-strength measurement supporting accelerated approval results in tangible improvements in patients’ function and daily lives.

The Bottom Line

SS-31, or elamipretide, is a mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. Under the brand name Forzinity, it received FDA accelerated approval in 2025 to improve muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kilograms.

That narrow approval is a major scientific and clinical development, but it does not support marketing elamipretide as a universal mitochondrial enhancer. Other proposed uses remain investigational unless separately approved, and evidence from cell experiments, animal studies, or subgroup analyses should not be presented as established human benefit.

Forzinity is a prescription medicine requiring professional oversight. Research-use-only SS-31 products are not substitutes for the approved drug and are not intended for human use. Patients should rely on qualified clinicians, official labeling, and credible medical sources rather than generalized wellness claims.

Elamipretide’s story is encouraging precisely because it shows how targeted science can advance from mitochondrial biology to an approved rare-disease treatment. It also demonstrates why careful evidence, accurate labeling, and continued clinical research remain essential.